122 related articles for article (PubMed ID: 24646480)
1. A snapshot of challenges and solutions in cancer drug development and therapy.
Phelps MA; Sparreboom A
Clin Pharmacol Ther; 2014 Apr; 95(4):341-6. PubMed ID: 24646480
[TBL] [Abstract][Full Text] [Related]
2. Molecularly targeted cancer therapy: some lessons from the past decade.
Huang M; Shen A; Ding J; Geng M
Trends Pharmacol Sci; 2014 Jan; 35(1):41-50. PubMed ID: 24361003
[TBL] [Abstract][Full Text] [Related]
3. [New anticancer drugs: much ado about nothing?].
Zimmermann S; Betticher D
Rev Med Suisse; 2014 Apr; 10(425):788, 790-3. PubMed ID: 24791424
[TBL] [Abstract][Full Text] [Related]
4. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
5. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
[TBL] [Abstract][Full Text] [Related]
6. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
7. Mathematical modeling in cancer drug discovery.
Wang Z; Deisboeck TS
Drug Discov Today; 2014 Feb; 19(2):145-50. PubMed ID: 23831857
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
9. Targeted cancer therapies: the future of cancer treatment.
Kumar M; Nagpal R; Hemalatha R; Verma V; Kumar A; Singh S; Marotta F; Jain S; Yadav H
Acta Biomed; 2012 Dec; 83(3):220-33. PubMed ID: 23762999
[TBL] [Abstract][Full Text] [Related]
10. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
11. The path to oncology drug target validation: an industry perspective.
Cortés-Cros M; Schmelzle T; Stucke VM; Hofmann F
Methods Mol Biol; 2013; 986():3-13. PubMed ID: 23436402
[TBL] [Abstract][Full Text] [Related]
12. Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies.
Rowinsky EK
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4220s-4226s. PubMed ID: 15217962
[TBL] [Abstract][Full Text] [Related]
13. The convergence of cancer prevention and therapy in early-phase clinical drug development.
Abbruzzese JL; Lippman SM
Cancer Cell; 2004 Oct; 6(4):321-6. PubMed ID: 15488755
[TBL] [Abstract][Full Text] [Related]
14. Novel cytotoxic drugs: old challenges, new solutions.
Ismael GF; Rosa DD; Mano MS; Awada A
Cancer Treat Rev; 2008 Feb; 34(1):81-91. PubMed ID: 17905518
[TBL] [Abstract][Full Text] [Related]
15. [Molecular targeted therapy for cancer].
Sone S; Kuramoto T; Sato S; Mitsuhashi A; Kakiuchi S; Goto H; Tada H; Nishioka Y
Nihon Rinsho; 2010 Jun; 68(6):997-1006. PubMed ID: 20535947
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.
Izar B; Rotow J; Gainor J; Clark J; Chabner B
Pharmacol Rev; 2013; 65(4):1351-95. PubMed ID: 24092887
[TBL] [Abstract][Full Text] [Related]
17. Molecular-targeted therapies: lessons from years of clinical development.
Rosa DD; Ismael G; Lago LD; Awada A
Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917
[TBL] [Abstract][Full Text] [Related]
18. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
Berns K; Bernards R
Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
[TBL] [Abstract][Full Text] [Related]
19. New targets and challenges in the molecular therapeutics of cancer.
Eastman A; Perez RP
Br J Clin Pharmacol; 2006 Jul; 62(1):5-14. PubMed ID: 16842374
[TBL] [Abstract][Full Text] [Related]
20. Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
André N; Padovani L; Pasquier E
Future Oncol; 2011 Mar; 7(3):385-94. PubMed ID: 21417902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
